This inventor holds 85 USPTO granted patents and 31 published patent applications, plus 9 CIPO patents and 12 EPO patents, primarily in Antibody Therapeutics (CPC class A61K2039-505). Top assignees: Visterra, Inc., Massachusetts Institute of Technology, Momenta Pharmaceuticals, Inc.. Active years: 2003-2025.
Inventors with similar research interests:
Location History:
- Boston, MA (US) (2005 - 2010)
- Cambridge, MA (US) (2003 - 2018)
- Winchester, MA (US) (2015 - 2024)
- Waltham, MA (US) (2023 - 2024)
Company Filing History:
32 out of 38 
27 out of 8,576 
25 out of 121 
Years Active: 2003-2025
Areas of Expertise:
Title: Zachary Shriver: Pioneering Innovations in Antibody Development
Introduction
Zachary Shriver, based in Cambridge, MA, is an accomplished inventor recognized for his significant contributions to the field of biotechnology. With an impressive portfolio of 81 patents, he has played a crucial role in the development of innovative therapies and diagnostic tools targeting various health conditions.
Latest Patents
Among his latest inventions are two groundbreaking patents focused on humanized complement 5A receptor 1 antibodies. The first patent, titled "Humanized complement 5A receptor 1 antibodies and methods of use thereof," provides detailed methodologies for treating dysfunctions related to the C5a/C5aR1 axis pathway, including ANCA-associated vasculitis. This patent outlines a method to administer effective amounts of antibodies or encoding nucleic acids to alleviate symptoms associated with this specific dysfunction.
The second patent, "Antibody molecules to C5AR1 and uses thereof," discloses antibody molecules designed to specifically bind to C5aR1. These novel molecules can potentially treat, prevent, and diagnose disorders such as ANCA-vasculitis, offering new hope for patients affected by this condition.
Career Highlights
Zachary Shriver has built his career at eminent institutions like Visterra, Inc. and the Massachusetts Institute of Technology (MIT). His role in these organizations has solidified his position as a leader in biopharmaceutical innovation, particularly in the development of antibody-based therapies.
Collaborations
Throughout his career, Zachary has collaborated with notable professionals, including Ganesh Venkataraman and Ram Sasisekharan. These partnerships have contributed to the advancement of research and development in antibody engineering and therapeutic applications, enhancing the potential impact of his innovations.
Conclusion
In summary, Zachary Shriver is a remarkable innovator whose work on antibodies targeting the C5a receptor represents a significant advance in medical science. His numerous patents and collaborations with leading experts underscore his commitment to improving patient outcomes through cutting-edge research and development.